CoChat

Inhibition of GPR35 Preserves Mitochondrial Function After Myocardial Infarction by Targeting Calpain 1/2

Open access
Chen, Ken, He, Lei, Li, Yong, Li, Xiuchuan, Qiu, Chenming, Pei, Haifeng, Yang, Dachun · 2020 · Journal of Cardiovascular Pharmacology

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Ischemia and anoxia-induced mitochondrial impairment may be a key factor leading to heart injury during myocardial infarction (MI). Calpain 1 and 2 are involved in the MI-induced mitochondria injury. G protein-coupled receptor 35 (GPR35) could be triggered by hypoxia. Whether or not GPR35 regulates calpain 1/2 in the pathogenesis of MI is still unclear. In this study, we determined that MI increases GPR35 expression in myocardial tissue. Suppression of GPR35 protects heart from MI injury in mice through reduction of reactive oxygen species activity and mitochondria-dependent apoptosis. Further studies show that GPR35 regulates calpain 1/2. Suppression of GPR35 reduces the expression and activity of calpain 1/2, and alleviates calpain 1/2-associated mitochondrial injury to preserve cardiac function. Based on these data, we conclude that a functional inhibition of GPR35 downregulates calpain 1/2 and contributes to maintenance of cardiac function under pathologic conditions with mitochondrial disorder. In conclusion, our study showed that the identified regulation by GPR35 of calpain 1/2 has important implications for the pathogenesis of MI. Targeting the action of GPR35 and calpain 1/2 in mitochondria presents a potential therapeutic intervention for MI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/fjc.0000000000000819

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1. The effect of MI on the GPR35 expression in myocardium. The GPR35 mRNA (A) and protein (B) expression in myocardium following MI were detected by RT-PCR and immunoblotting (*P < 0.05, vs. sham, n = 6).
FIGURE 1. The effect of MI on the GPR35 expression in myocardium. The GPR35 mRNA (A) and protein (B) expression in myocardium following MI were detected by RT-PCR and immunoblotting (*P < 0.05, vs. sham, n = 6).CC BY-NC-ND · PubMed Central
FIGURE 2. The effect of anoxia on the GPR35 expression in NMVMs. The GPR35 mRNA (A) and protein (B) expression in NMVMs after 12 or 24-hour anoxia were detected by RT-PCR and immunoblotting (*P < 0.05, vs. control, n = 6).
FIGURE 2. The effect of anoxia on the GPR35 expression in NMVMs. The GPR35 mRNA (A) and protein (B) expression in NMVMs after 12 or 24-hour anoxia were detected by RT-PCR and immunoblotting (*P < 0.05, vs. control, n = 6).CC BY-NC-ND · PubMed Central
FIGURE 3. GPR35 inhibition protected against MI in the mouse heart. A, The animal survival rate after MI with GPR35 siRNA treatment (*P < 0.05, vs. others; n = 21). B, The fibrosis of myocardium after MI was detected by Masson staining. The fibrotic area (blue) were calculated as a percentage of total LV area (*P < 0.05, vs. others; n = 6, scale bar = 1 mm). C and D, The cardiac function parameters including LVFS (C) and LVEF (D) were measured by echocardiography (*P < 0.05, vs. others; n = 6).
FIGURE 3. GPR35 inhibition protected against MI in the mouse heart. A, The animal survival rate after MI with GPR35 siRNA treatment (*P < 0.05, vs. others; n = 21). B, The fibrosis of myocardium after MI was detected by Masson staining. The fibrotic area (blue) were calculated as a percentage of total LV area (*P < 0.05, vs. others; n = 6, scale bar = 1 mm). C and D, The cardiac function parameters including LVFS (C) and LVEF (D) were measured by echocardiography (*P < 0.05, vs. others; n = 6).CC BY-NC-ND · PubMed Central
FIGURE 4. GPR35 inhibition protected against anoxia injury in NMVMs. A, Mitochondrial ATP production was checked by an assay kit. The result was expressed as a percentage of control (*P < 0.05, vs. others; n = 6). B, MMP was assessed using JC-1 kit. Fluorescence intensity values were each expressed as ratios of emission at 590 to that at 530 nm. The result was expressed as a percentage of control (*P < 0.05, vs. others; n = 6). C and D, The extent of ROS production in NMVMs was determined by DHE staining (C) and lucigenin-enhanced luminescence assay (D) (*P < 0.05, vs. others; n = 6, scale bar = 10 µm). E, The mitochondrial morphology was observed by electron microscopy. Anoxia led to a marked swollen and disruption of cristae of mitochondrial in NMVMs, and GPR35 antagonist, CID2745678, alleviated the MI-induced mitochondrial injury (scale bar = 500 nm). F, The cell apoptosis was tested using flow cytometry analysis after Annexin V/PI staining. The data were analyzed by FlowJo 10.0 software (*P < 0.05, vs. others; n = 6). G, Anoxia treatment enhanced caspase-3 and -9 activation in NMVMs, whereas CID2745678 treatment reduced anoxia-induced caspase-3 and -9 activation (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6).
FIGURE 4. GPR35 inhibition protected against anoxia injury in NMVMs. A, Mitochondrial ATP production was checked by an assay kit. The result was expressed as a percentage of control (*P < 0.05, vs. others; n = 6). B, MMP was assessed using JC-1 kit. Fluorescence intensity values were each expressed as ratios of emission at 590 to that at 530 nm. The result was expressed as a percentage of control (*P < 0.05, vs. others; n = 6). C and D, The extent of ROS production in NMVMs was determined by DHE staining (C) and lucigenin-enhanced luminescence assay (D) (*P < 0.05, vs. others; n = 6, scale bar = 10 µm). E, The mitochondrial morphology was observed by electron microscopy. Anoxia led to a marked swollen and disruption of cristae of mitochondrial in NMVMs, and GPR35 antagonist, CID2745678, alleviated the MI-induced mitochondrial injury (scale bar = 500 nm). F, The cell apoptosis was tested using flow cytometry analysis after Annexin V/PI staining. The data were analyzed by FlowJo 10.0 software (*P < 0.05, vs. others; n = 6). G, Anoxia treatment enhanced caspase-3 and -9 activation in NMVMs, whereas CID2745678 treatment reduced anoxia-induced caspase-3 and -9 activation (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6).CC BY-NC-ND · PubMed Central
FIGURE 5. GPR35 inhibition suppresses anoxia-induced calpain 1/2 activation. A, The calpain activation was checked by a fluorescence substrate kit (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6). B and C, GPR35 inhibition suppresses the mRNA (B) and protein (C) expression of calpain 1/2 after anoxia treatment (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6).
FIGURE 5. GPR35 inhibition suppresses anoxia-induced calpain 1/2 activation. A, The calpain activation was checked by a fluorescence substrate kit (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6). B and C, GPR35 inhibition suppresses the mRNA (B) and protein (C) expression of calpain 1/2 after anoxia treatment (*P < 0.05, vs. others, #P < 0.05, vs. anoxia group; n = 6).CC BY-NC-ND · PubMed Central
FIGURE 6. GPR35 inhibition suppresses calpain 1/2 overexpression-induced cardiac dysfunction. The cardiac function parameters including LVFS (A) and LVEF (B) were measured by echocardiography (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6).
FIGURE 6. GPR35 inhibition suppresses calpain 1/2 overexpression-induced cardiac dysfunction. The cardiac function parameters including LVFS (A) and LVEF (B) were measured by echocardiography (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6).CC BY-NC-ND · PubMed Central
FIGURE 7. GPR35 inhibition suppresses calpain 1/2 overexpression-induced mitochondrial dysfunction in NMVMs. A, Mitochondrial ATP production was checked by an assay kit. The result was expressed as a percentage of control (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6). B, MMP was assessed using JC-1 kit. Fluorescence intensity values were each expressed as ratios of emission at 590 to that at 530 nm. The result was expressed as a percentage of control (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6). C, The extent of ROS production in NMVMs was determined by lucigenin-enhanced luminescence assay (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6).
FIGURE 7. GPR35 inhibition suppresses calpain 1/2 overexpression-induced mitochondrial dysfunction in NMVMs. A, Mitochondrial ATP production was checked by an assay kit. The result was expressed as a percentage of control (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6). B, MMP was assessed using JC-1 kit. Fluorescence intensity values were each expressed as ratios of emission at 590 to that at 530 nm. The result was expressed as a percentage of control (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6). C, The extent of ROS production in NMVMs was determined by lucigenin-enhanced luminescence assay (*P < 0.05, vs. others, #P < 0.05, vs. calpain 1/2 overexpression group; n = 6).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 19

Metadata

Authors
Chen, K., He, L., Li, Y., Li, X., Qiu, C., Pei, H., & Yang, D.
Affiliations
  • Army Medical University (CN)
  • Chengdu Military General Hospital (CN)
  • Department of Cardiology, The People's Hospital of Chaotian District in Guangyuan, Guangyuan, Sichuan, P.R. China.
Corresponding author
  • Chen, Ken
  • He, Lei
  • Li, Xiuchuan
  • Qiu, Chenming
  • Pei, Haifeng
  • Yang, Dachun
Venue
Journal of Cardiovascular Pharmacology
Published
2020-04-15
Volume
75
Issue
6
Pages
556-563
ISSN
0160-2446 (ISSN-L)
OpenAlex
W3012231107
Cited by
19
References
39
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3
FWCI
1.25
Type
journal article
Language
en
Open access
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81470396, 81770299)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Calpain Protease Function and Regulation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
GPR35, myocardial infarction, mitochondrial dysfunction, ischemia-reperfusion injury, reactive oxygen species, mitochondrial apoptosis, cardiac function, G protein-coupled receptors, therapeutic target
MeSH terms
RNAi Therapeutics, Animals, Calpain, Cells, Cultured, Disease Models, Animal, Male, Mice, Inbred C57BL, Mitochondria, Heart, Myocardial Infarction, Signal Transduction, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Myocytes, Cardiac, RNA, Small Interfering, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of GPR35 Preserves Mitochondrial Function After Myocardial Infarction by Targeting Calpain 1/2. https://app.cochat.ai/papers/10.1097/fjc.0000000000000819
The paper
Chen, K., He, L., Li, Y., Li, X., Qiu, C., Pei, H., & Yang, D. (2020). Inhibition of GPR35 Preserves Mitochondrial Function After Myocardial Infarction by Targeting Calpain 1/2. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000000819

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.